What is 89bio Financial Strength?
89bio has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
89bio Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
89bio did not have earnings to cover the interest expense.
As of today, 89bio's Altman Z-Score is 0.00.
Competitive Comparison of 89bio's Financial Strength
For the Biotechnology subindustry, 89bio's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
89bio's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 89bio's Financial Strength distribution charts can be found below:
* The bar in red indicates where 89bio's Financial Strength falls into.
89bio Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
89bio's Interest Expense for the
months ended in Mar. 2024 was $-0.86 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-57.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $24.71 Mil.
89bio's Interest Coverage for the quarter that ended in Mar. 2024 is
| 89bio did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
89bio's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
89bio has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
89bio (ETNB) Business Description
Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
| Kathleen Laporte |
director |
|
| Rohan Palekar |
director, officer: Chief Executive Officer |
201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
| Atkinson Edward Morrow Iii |
director |
C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104 |
| Quoc Le-nguyen |
officer: See Remarks |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Ryan Martins |
officer: Chief Financial Officer |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Michael R Hayden |
director |
C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ra Capital Nexus Fund, L.p. |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ram Waisbourd |
officer: See Remarks |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Orbimed Advisors Llc |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Gregory Grunberg |
director, 10 percent owner |
100 BEAVER STREET, WALTHAM MA 02453 |
| Anat Naschitz |
director, 10 percent owner |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Longitude Capital Partners Iii, Llc |
10 percent owner |
800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
| Lota S. Zoth |
director |
334 CR 692, BUFFALO GAP TX 79508 |
| Steven Altschuler |
director |
MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ETNB has been successfully added to your